Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIXC NASDAQ:ATRA NASDAQ:ETHZ NASDAQ:RANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIXCQualigen Therapeutics$1.08+3.2%$1.34$0.92▼$8.81$21.25M0.5150,917 shs70,485 shsATRAAtara Biotherapeutics$10.51+2.8%$8.65$3.92▼$19.15$92.08M0.1184,153 shs45,296 shsETHZFlag Ship Acquisition$5.20+2.6%$4.65$0.70▼$17.46$98.86M1.176.44 million shs297,949 shsRANIRani Therapeutics$0.74-0.9%$0.90$0.39▼$3.87$91.96M0.74760,181 shs825,210 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIXCQualigen Therapeutics-11.76%-28.08%-17.97%-8.70%+104,999,900.00%ATRAAtara Biotherapeutics-3.13%+1.49%+6.35%+122.66%+27.43%ETHZFlag Ship Acquisition+0.80%-0.20%+11.67%+77.89%+506,999,900.00%RANIRani Therapeutics-3.22%-5.13%-21.07%-8.43%+45.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIXCQualigen Therapeutics$1.08+3.2%$1.34$0.92▼$8.81$21.25M0.5150,917 shs70,485 shsATRAAtara Biotherapeutics$10.51+2.8%$8.65$3.92▼$19.15$92.08M0.1184,153 shs45,296 shsETHZFlag Ship Acquisition$5.20+2.6%$4.65$0.70▼$17.46$98.86M1.176.44 million shs297,949 shsRANIRani Therapeutics$0.74-0.9%$0.90$0.39▼$3.87$91.96M0.74760,181 shs825,210 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIXCQualigen Therapeutics-11.76%-28.08%-17.97%-8.70%+104,999,900.00%ATRAAtara Biotherapeutics-3.13%+1.49%+6.35%+122.66%+27.43%ETHZFlag Ship Acquisition+0.80%-0.20%+11.67%+77.89%+506,999,900.00%RANIRani Therapeutics-3.22%-5.13%-21.07%-8.43%+45.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIXCQualigen Therapeutics 1.00SellN/AN/AATRAAtara Biotherapeutics 2.00Hold$9.50-9.61% DownsideETHZFlag Ship Acquisition 1.00SellN/AN/ARANIRani Therapeutics 2.60Moderate Buy$8.751,089.02% UpsideCurrent Analyst Ratings BreakdownLatest AIXC, ETHZ, ATRA, and RANI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026RANIRani Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/11/2026ATRAAtara Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (E+)5/20/2026RANIRani Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.005/18/2026ATRAAtara Biotherapeutics Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/8/2026ATRAAtara Biotherapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold ➝ Buy$6.00 ➝ $13.005/8/2026ATRAAtara Biotherapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$13.004/24/2026AIXCQualigen Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/14/2026RANIRani Therapeutics Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.004/1/2026RANIRani Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $5.003/27/2026ATRAAtara Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)3/27/2026RANIRani Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIXCQualigen TherapeuticsN/AN/AN/AN/A($0.75) per shareN/AATRAAtara Biotherapeutics$120.77M0.78$5.00 per share2.10($5.34) per share-1.97ETHZFlag Ship Acquisition$4.11M24.05N/AN/A$29.12 per share0.18RANIRani Therapeutics$1.63M55.93N/AN/A$0.34 per share2.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIXCQualigen Therapeutics-$16.97M-$6.47N/AN/AN/AN/A-771.52%-79.52%N/AATRAAtara Biotherapeutics$32.69M-$0.67N/A7.51N/A-40.91%-79.12%-35.29%8/10/2026 (Estimated)ETHZFlag Ship Acquisition-$6.17M-$159.65N/AN/AN/AN/A-185.71%-83.12%N/ARANIRani Therapeutics-$29.67M-$0.41N/AN/AN/AN/A-206.46%-83.95%8/6/2026 (Estimated)Latest AIXC, ETHZ, ATRA, and RANI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026RANIRani Therapeutics-$0.06-$0.04+$0.02-$0.04$1.13 million$1.71 million5/12/2026Q1 2026AIXCQualigen TherapeuticsN/A-$0.79N/A-$0.79N/AN/A5/12/2026Q1 2026ATRAAtara Biotherapeutics-$0.3295-$0.29+$0.0395-$0.29$2.90 million$0.52 million3/30/2026Q4 2025AIXCQualigen TherapeuticsN/A-$3.76N/A-$3.76N/AN/A3/26/2026Q4 2025RANIRani Therapeutics-$0.03-$0.07-$0.04-$0.07$5.00 million$1.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIXCQualigen TherapeuticsN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AETHZFlag Ship AcquisitionN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIXCQualigen TherapeuticsN/A11.5711.57ATRAAtara BiotherapeuticsN/A2.162.16ETHZFlag Ship Acquisition1.1110.0710.07RANIRani TherapeuticsN/A3.403.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIXCQualigen Therapeutics3.18%ATRAAtara Biotherapeutics70.90%ETHZFlag Ship Acquisition4.07%RANIRani Therapeutics30.19%Insider OwnershipCompanyInsider OwnershipAIXCQualigen Therapeutics1.17%ATRAAtara Biotherapeutics41.20%ETHZFlag Ship Acquisition15.10%RANIRani Therapeutics26.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIXCQualigen Therapeutics5020.24 million20.00 millionN/AATRAAtara Biotherapeutics3309.01 million5.30 millionNo DataETHZFlag Ship Acquisition719.01 million16.14 millionN/ARANIRani Therapeutics110123.88 million90.77 millionOptionableAIXC, ETHZ, ATRA, and RANI HeadlinesRecent News About These CompaniesRani Therapeutics Shareholders Back Board and Auditor at MeetingMay 29, 2026 | tipranks.comRani Therapeutics Announces $20 Million Equity FinancingMay 27, 2026 | tipranks.comRani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq RulesMay 26, 2026 | globenewswire.comRani Therapeutics Faces Nasdaq Bid Price Noncompliance NoticeMay 17, 2026 | theglobeandmail.comNasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid PriceMay 17, 2026 | tipranks.comRani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO TransitionMay 15, 2026 | globenewswire.comRani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor ConferenceMay 12, 2026 | globenewswire.comThis Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last YearMay 9, 2026 | finance.yahoo.comRani Therapeutics Holdings (RANI) price target decreased by 12.50% to 7.14April 9, 2026 | msn.comRani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical StrategyApril 9, 2026 | globenewswire.comThe Oral Delivery Revolution: Rani Therapeutics' Strategic PositionApril 2, 2026 | aktiencheck.deARani Therapeutics Holdings (RANI) price target decreased by 13.51% to 8.16March 27, 2026 | msn.comRani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | seekingalpha.comRani Therapeutics Powers Ahead with Record-Breaking Q4 Results, Fueling Pipeline Growth and Platform ExpansionMarch 26, 2026 | news.themarketisopen.comNRani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate UpdateMarch 26, 2026 | globenewswire.comRani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline PrioritizationMarch 25, 2026 | globenewswire.comWhat To Expect From Rani Therapeutics Holdings Inc (RANI) Q4 2025 EarningsMarch 25, 2026 | finance.yahoo.comMaxim Group Keeps Their Buy Rating on Rani Therapeutics Holdings (RANI)March 21, 2026 | theglobeandmail.comRani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial ResultsMarch 19, 2026 | globenewswire.comRani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical OfficerJanuary 28, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAIXC, ETHZ, ATRA, and RANI Company DescriptionsQualigen Therapeutics NASDAQ:AIXC$1.08 +0.03 (+3.24%) Closing price 03:57 PM EasternExtended Trading$1.07 -0.01 (-1.29%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.Atara Biotherapeutics NASDAQ:ATRA$10.51 +0.29 (+2.84%) As of 04:00 PM EasternAtara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Flag Ship Acquisition NASDAQ:ETHZ$5.20 +0.13 (+2.56%) As of 06/25/20261180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.Rani Therapeutics NASDAQ:RANI$0.74 -0.01 (-0.86%) Closing price 04:00 PM EasternExtended Trading$0.74 0.00 (-0.12%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab's NASA Win Tests Key Support After Sharp Pullback BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Xcel Energy Stock Offers Stability as Electricity Demand Builds Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
